We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
-$15.9M
Cap. Flow %
-0.61%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
76
DELISTED
PRA Health Sciences, Inc.
PRAH
$5.76M 0.22%
102,000
– –
XENE icon
77
Xenon Pharmaceuticals
XENE
$6.2B
$5.67M 0.22%
+700,000
New +$5.41M
ICLR icon
78
Icon
ICLR
$12.8B
$5.57M 0.21%
72,000
– –
LTC
79
LTC Properties
LTC
$2.06B
$5.52M 0.21%
106,212
– –
JUNO
80
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.46M 0.21%
182,000
– –
VTAE
81
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$5.23M 0.2%
+250,000
New +$2.88M
ASRT
82
DELISTED
Assertio
ASRT
$5M 0.19%
3,333
– –
SNR
83
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$4.97M 0.19%
+430,997
New +$5.09M
KPTI icon
84
Karyopharm Therapeutics
KPTI
$159M
$4.87M 0.19%
33,355
– –
BHC icon
85
Bausch Health
BHC
$2.25B
$4.71M 0.18%
192,000
– –
MRUS
86
DELISTED
Merus
MRUS
$4.36M 0.17%
260,000
– –
MNK
87
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.32M 0.17%
61,900
-162,000
-72% -$11.7M
AGN.PRA
88
DELISTED
Allergan plc
AGN.PRA
$4.11M 0.16%
5,000
– –
ADAP
89
DELISTED
Adaptimmune Therapeutics
ADAP
$3.99M 0.15%
566,368
+269,434
+91% +$2.06M
AKRX
90
DELISTED
Akorn Inc
AKRX
$3.96M 0.15%
145,235
-100,000
-41% -$2.96M
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$3.94M 0.15%
400,000
– –
THC icon
92
Tenet Healthcare
THC
$21.8B
$3.73M 0.14%
164,500
– –
DVAX
93
DELISTED
Dynavax Technologies
DVAX
$3.62M 0.14%
345,050
– –
ONC
94
BeOne Medicines Ltd
ONC
$33.4B
$3.6M 0.14%
116,707
– –
ACAD icon
95
Acadia Pharmaceuticals
ACAD
$4.55B
$3.56M 0.14%
111,800
-251,785
-69% -$8.54M
CYH icon
96
Community Health Systems
CYH
$391M
$3.51M 0.14%
304,472
– –
PRGO icon
97
Perrigo
PRGO
$1.43B
$3.44M 0.13%
37,300
– –
BLUE
98
DELISTED
bluebird bio
BLUE
$3.35M 0.13%
3,809
– –
AXDX
99
DELISTED
Accelerate Diagnostics
AXDX
$3.27M 0.13%
12,000
-14,463
-55% -$3.2M
IPXL
100
DELISTED
Impax Laboratories, Inc.
IPXL
$2.95M 0.11%
124,335
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.